Novartis
NEWS
As Britain’s “Brexit” from the European Union moves closer and closer, the European Medicines Agency (EMA), the equivalent to the U.S. Food and Drug Administration (FDA), temporary halted some of its activities in preparation.
Laekna, headquartered in Shanghai, China, signed a deal with Novartis Pharma AG for exclusive worldwide rights to two oral Novartis clinical-stage cancer drugs.
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.
BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.
Before taking over the helm of Novartis AG, Vasant Narasimhan pointed to the harnessing of digital technology as a key method of saving a significant percentage of clinical trial costs.
Boston-based resTORbio, which was spun out of Novartis in April 2017, announced positive topline results from its Phase IIb clinical trial of RTB101 in patients with respiratory tract infections (RTIs).
If there’s one thing that defines the tenure of FDA Commissioner Scott Gottlieb, it is his outspoken mission to lower drug prices by introducing more competition into the biopharmaceutical market. And a big part of that mission has been doing what he can to boost the nascent biosimilar industry.
It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
JOBS
IN THE PRESS